Purdue Researchers Develop Next-Generation Automated Platform to Accelerate Drug Discovery – Purdue Institute for Cancer Research

oncodaily - Purdue Institute for Cancer Research shared a post on LinkedIn: “Purdue researchers, including Nicolás Morato and R. Graham Cooks, have developed a next-generation platform that integrates chemical synthesis, biological testing, […]

AI Summary: Purdue researchers unveiled an automated mass‑spectrometry platform that compresses key steps of small‑molecule drug discovery into a matter of hours, promising faster lead identification and screening. The system couples high‑throughput chemistry with rapid readouts to accelerate iteration cycles, potentially shrinking timelines and costs for early oncology drug development — welcome news for impatient scientists.

#pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch

46 hrs / oncodaily


Back to Top / Sat, June 20, 2026, 12:21 pm / permalink 25600 / 2 stories in 2 hrs /




Related Stories


Engineered CAR‑T cells secreting VEGF‑neutralizing scFvs boost solid‑tumor activity / 3 months

Some tumors kill neighboring healthy cells to fuel growth / 13 days

Zanidatamab improves PFS over trastuzumab in HER2 GEA / 19 days

MAGE‑A4/A8 TCR bispecific T‑cell engager shows activity in solid tumors / 19 days

Teclistamab outperforms standard regimens in earlier-line relapsed myeloma / 21 days

Common asthma drug may overcome immunotherapy resistance in cancers / 4 wks

Retifanlimab plus chemotherapy extends survival in advanced squamous anal cancer / 4 wks

StackHealth RSS


You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Gene Therapy, Healthcare, Trump Administration, Infant Health and look for the RSS link.





NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.